Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non‐inferiority randomised controlled trials
Alimentary Pharmacology & Therapeutics2016Vol. 45(2), pp. 240–252
Citations Over TimeTop 10% of 2016 papers
Hiroto Miwa, Noriya Uedo, Jiro Watari, Yujiro Mori, Yuichi Sakurai, Yohei Takanami, Akira Nishimura, T Tatsumi, Nobuhiro Sakaki
Abstract
Vonoprazan 20 mg has a similar tolerability profile to lansoprazole 30 mg and is non-inferior with respect to GU healing and has similar efficacy for DU healing.
Related Papers
- → Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: A comparison between two different daily doses of lansoprazole(2006)66 cited
- Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.(1996)
- → Effects of Lansoprazole on Ethanol-Induced Injury and PG Synthetic Activity in Rat Gastric Mucosa(1995)18 cited
- → Determining the Optimal Dose of Lansoprazole Injection by 24-Hour Intragastric pH Monitoring(1995)3 cited
- Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough： A comparison between two different daily doses of lansoprazole(2006)